-
Merlin-timi 36 tested the hypothesis that ranolazine, a recently approved anti-anginal agent, would benefit patients with non-ST-elevation acute coronary syndrome (NSTEACS).
-
Despite impressive reductions in cardiovascular risk in primary and secondary prevention trails with statin therapy, risk does not reach zero.
-
For patients presenting with acute coronary syndromes (ACS), the optimal doses of aspirin and clopidogrel remain unknown.
-
The U.S. HIV epidemic has claimed more than 575,000 lives, and 56,300 Americans were newly infected with HIV in 2006.
-
Scientists have discovered two potent human antibodies that can neutralize more than 90% of known global HIV strains from infecting human cells in the laboratory, and they have demonstrated how one of these disease-fighting proteins achieves this action.
-
The search for a female-controlled form of HIV prevention just took a giant step. Results of a Phase IIB trial of a tenofovir gel indicate that use of the gel before and after sex provided moderate protection against sexually transmitted HIV.
-
Metro TeenAIDS of Washington, DC, works to reduce HIV risk among youth in a city that is among the hardest hit areas of the country in terms of the HIV epidemic.
-
Perhaps the most surprising news in the Centers for Disease Control and Prevention's (CDC's) recent report linking poverty to a generalized HIV epidemic in urban communities across the United States was that race played far less of a role than many people would imagine. The biggest factor was poverty in an urban community.
-
-
Despite the HIV epidemic's impact on poor, urban African Americans nationwide, there have been few prevention interventions targeting this population specifically.